Health and Biosecurity Governance
The Global Risks Forum (GRF)
In a health emergency, vaccines, diagnostics, therapeutics and protective equipment must be developed, approved, made and delivered at speed. Manufacturing is concentrated in a few countries, and allocation becomes a political contest. This page sets out how medical countermeasure governance works and where it fails, the records that show access and supply, and who decides.
Vaccine and medical supply governance · Supply coordination cell · Quarter 3
| Antivirals | 11 | In place | Priority groups |
| Diagnostics | 2 | Renewing | By positivity |
| Protective equipment | 14 | In place | By facility tier |
Fig.Countermeasure supply governance. Design wireframe with placeholder names and illustrative values, not a record or a live system.
Vaccine and medical supply governance is the set of rules and institutions that decide how vaccines, diagnostics, therapeutics and protective equipment are approved, made, bought and allocated in emergencies. Concentrated manufacturing, advance purchases and regulatory capacity shape access. Regulators, health ministries and pooled mechanisms hold the decisions.
For vaccine and medical supply governance, in GRF's situational-awareness reading, the map opens on population density, flood water and night lights with nitrogen dioxide from NASA GIBS, framed on Southern Africa; 3 further NASA layers wait in the list.
The interactive map needs JavaScript; the layer list and sources are below.
Layers 3
Environmental exposure, for this page
Keyboard, with the map focused
Hold Ctrl or ⌘ and scroll to zoom
Latest available
NASA GIBS / EOSDIS · ASTER GDEM (METI, NASA) · Blue Marble (NASA) · © OpenStreetMap contributors (ODbL) · Natural Earth
Loading the latest NASA imagery.
Drag to move. Ctrl or ⌘ and scroll, pinch or the buttons to zoom; hover for the values under the pointer; reset returns to the region.
For vaccine and medical supply governance, in GRF's situational-awareness reading, the map opens on population density, flood water and night lights with nitrogen dioxide from NASA GIBS, framed on Southern Africa; 3 further NASA layers wait in the list.Satellite and model products as NASA publishes them, each with its own date; indicators, not assessments of any place; claim ceiling INTEGRATED.
Layers and dates
Access, procurement authority and resilience. The dossier below sets out how the risk develops, what is measured, where the data come from, how it is modelled and who decides.
A few countries and firms produce most vaccines and key inputs. Export restrictions and advance purchases by wealthy states leave others waiting.
Countries without mature regulators rely on WHO prequalification or reliance pathways. Duplicated reviews and unclear emergency use rules delay access.
Contracts signed before products exist reserve supply for those who can pay and bear risk. Pooled mechanisms depend on donors and on manufacturers honouring commitments.
Cold chain, workforce and demand decide whether doses become vaccinations. Supply without delivery capacity leads to expiry and waste.
Each term as this page uses it. Where a standard-setting body defines the term, the wording follows that body.
| Term | Definition |
|---|---|
| WHO prequalification | WHO's assessment of health products against quality, safety and efficacy standards, used to guide UN and national procurement. |
| Regulatory reliance | A regulator taking account of a trusted regulator's assessment when reaching its own decision. |
| Advance purchase agreement | A contract to buy a product before it is approved, reserving supply in exchange for funding or risk-sharing. |
Each indicator carries its unit, its cadence, the kind of source behind it and the evidence label a value would carry. No values are shown: a programme supplies them under its own authority.
| Indicator | Unit | Cadence | Source type | Label |
|---|---|---|---|---|
| Regulatory system maturity level | WHO Global Benchmarking maturity level | on assessment | WHO records | OFFICIAL |
| Vaccine doses delivered per population | doses per hundred people | monthly in emergencies | WHO and UNICEF dashboards | REPORTED |
| Time from first approval to first delivery by income group | days | per product | Market and regulatory records | ESTIMATED |
| Regional manufacturing capacity | doses per year | periodic | Industry and agency surveys | REPORTED |
| Export restrictions on medical goods | count of measures | during emergencies | Trade monitoring | REPORTED |
| Doses expired before use | count | per campaign | Programme records | REPORTED |
The topic as a computational graph: named sources feed the methods, an evidence review gates the outputs, and the decisions stay with the authorities that hold them.
Fig. 02Nodes carry their type, two metric rows and a state; connectors show what feeds what; dashed frames name the owners; the timeline is the cadence. Design of the pipeline, not a record of a run.
Named public datasets and institutional records, each with its licence class. Sources by agreement are used only under their terms and never republished.
| Source | What it gives | Licence class |
|---|---|---|
| WHO Prequalification and Global Benchmarking Tool records | Prequalified products and regulator maturity levels | Free, WHO terms |
| UNICEF Supply Division market dashboards | Vaccine supply, prices and deliveries | Free to read, UNICEF terms |
| Gavi and COVAX records | Allocation and delivery of vaccines | Free to read, terms to check |
| WTO trade monitoring on medical goods | Trade measures affecting medical products | Free, WTO terms |
| African Medicines Agency and regional regulatory records | Regional regulatory cooperation | Public records, terms per agency |
Health and Biosecurity Governance prepares evidence. The decisions below are taken by the authorities named, under their own rules, and never by the platform.
| Who decides | The question | Evidence this page serves |
|---|---|---|
| National regulatory authorities | Whether and how to authorise products in an emergency | Reliance pathways and comparable decisions |
| Health ministries and procurement agencies | What to buy, when and through which mechanism | Supply, price and delivery records |
| Governments of manufacturing countries | Whether to restrict exports or share supply | Trade measure records and their effects |
| Boards of Gavi, CEPI and similar bodies | How to allocate funds and doses | Allocation records and evaluations |
The questions concern access, authority and resilience.
Manufacturing capacity for vaccines and many medicines is concentrated in a limited number of countries and firms. In emergencies, countries with purchasing power and domestic production can secure supply first, while others wait. Pooled procurement and regional manufacturing are among the responses to this inequity.
Regulatory processes determine how quickly products reach people. Reliance on assessments by trusted regulators and emergency procedures can speed access but require trust and capacity. Allocation frameworks must balance health need, risk of exposure, protection of health workers and equity.
| Method or data | What it shows | Limits |
|---|---|---|
| Procurement and contract analysis | Terms of purchase and supply | Many contracts are confidential |
| Allocation framework comparison | How priorities are set | Implementation may differ from frameworks |
| Supply-chain mapping | Concentration and dependencies | Firm-level data is limited |
| Regulatory reliance analysis | How regulators cooperate | Practices are changing |
The current service level is R0: information and enquiries. An enquiry receives a reference and names the next step; applications, payments, compute allocations and registrations open only when their team, terms and review capacity exist.